Tislelizumab Plus FOLFOX Versus POF in the Treatment of Locally Advanced: a Multicenter, Open-label, Randomized Phase III Studyunresectable or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma

NCT06793917 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

269

Enrollment

OTHER_GOV

Sponsor class

Conditions

Gastric Cancer

Interventions

DRUG: Tislelizumab
DRUG: Oxaliplatin injection
DRUG: Levo-Leucovorin
DRUG: 5-fluorouracil
DRUG: Paclitaxel

Sponsor

Fujian Cancer Hospital